Global Malignant Melanoma Treatment Market, By Stage (Stage 0, Stage I, Stage II, Stage III, Stage IV, Recurrent), Therapy (Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Inhibitors), Drugs (Opdivo, Yervoy, Mekinist+Tafinlar, Keytruda, Cotellic, Zelboraf, Imlygic, Generic Drugs) – Industry Trends and Forecast to 2030.
Malignant Melanoma Treatment Market Analysis and Size
The increase in the cases of melanoma and other skin cancers among the population across the globe and technological advancement to enhance cancer treatment are the major factors driving the malignant melanoma treatment market. The factors such as long working hours in airplanes, the rise in the use of tanning beds and exposure to ultraviolet rays, and the decrease in ozone levels also influence the malignant melanoma treatment market by raising cancer incidences. The increase in the need for effective immune therapies, penetration of premium drug products, and the adoption rate of advanced technologies accelerate the malignant melanoma treatment market. Additionally, initiatives taken by the government to spread awareness about the early diagnosis and treatment and launch of new targeted therapeutic methods such as vaccines and immunotherapy positively affect the malignant melanoma treatment market. Furthermore, the rise in the adoption of novel therapeutics and the growing number of approvals for the Food and Drug Administration extend profitable opportunities to the malignant melanoma treatment market players in the forecast period.
Data Bridge Market Research analyzes that the global malignant melanoma treatment market, which was USD 6.37 billion in 2022, would rocket up to USD 14.12 billion by 2030 and is expected to undergo a CAGR of 11.8% from 2023 to 2030. This indicates the market value. “Stage 0” dominates the stage segment of the global malignant melanoma treatment market owing to the increasing number of skin cancer. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Malignant Melanoma Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Year
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Stage (Stage 0, Stage I, Stage II, Stage III, Stage IV, Recurrent), Therapy (Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Inhibitors), Drugs (Opdivo, Yervoy, Mekinist+Tafinlar, Keytruda, Cotellic, Zelboraf, Imlygic, Generic Drugs)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina, and rest of South America
|
|
Market Players Covered
|
Biogen (US), Bristol-Myers Squibb Company (US), Enzon Pharmaceuticals Inc. (US), GlaxoSmithKline plc (UK), Aptose Biosciences (Canada), Merck KGaA (Germany), ONO PHARMACEUTICAL CO. LTD.(Japan), DAIICHI SANKYO COMPANY LIMITED (Japan), Reliance Industries Limited (India), among other
|
|
Market Opportunities
|
|
Market Definition
Malignant melanoma refers to uncontrolled cell growth, which develops from melanocytes which are the pigment-producing cells in the body. Their cases have increased in the past few years worldwide, and they are rarely seen in the eyes, mouth, or intestine. They generally occur on the back of men and the legs of women. This cancer occur approximately 25% from moles.
Global Malignant Melanoma Treatment Market Dynamics
Drivers
- Notable Developments in terms of Market Players
Recently, there have been some promising and innovative developments in the global malignant melanoma market. The market has observed the presence of several noticeable market players, with each of the players competing for more revenue and greater reach. Relentless research and development activities have played a critical role in the expansion of the share of the market and growing revenue for the market players. This boosts market growth.
- Increasing Demand for Targeted Therapy
The rising demand for targeted therapy showed many advantages as it interferes with specific proteins involved in tumorigenesis, focusing on specific molecular changes, which stop the growth of various types of cancers. Several significant factors influenced melanoma growth, including the fewer adverse effects of the therapy and the availability of several targeted therapeutics. This boosts market growth.
Opportunities
Growing Healthcare Infrastructure and Policies
The presence of large patient pool, having a strong presence of key players, ease of drug availability, a well-established healthcare infrastructure, favourable reimbursement policies in the healthcare system, rise in R&D, and innovation activities and higher adoption of advanced therapeutics may create opportunities for the market.
Restraints/Challenges
Unavailability of Appropriate Treatments
To treat conditions that are rare, many a times all treatments are not available, especially in under-developed countries. Severe patients need to be treated with advanced techniques, but these are sometimes unavailable in the hospitals and clinics. Thus, it hampers the market growth.
This global malignant melanoma treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyzes opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, and technological innovations in the market. To gain more info on the surgical microscopes market contact Data Bridge Market Research for an Analyst Brief, our team will help you make an informed market decision to achieve market growth.
Recent Developments
- In 2020, FDA approved the drug selumetinib of AstraZeneca and Merck & Co. to treat neurofibromatosis type 1, or NF1, a rare and characteristically inherited disease that causes tumors to grow inside nerve sheaths. In addition to this, Merck joined AstraZeneca in developing and commercializing Koselugo as part of a deal that included the ovarian cancer drug Lynparza.
Global Malignant Melanoma Treatment Market Scope
The global malignant melanoma treatment market is segmented on the basis of stage, therapy and drugs. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Stage
- STAGE 0
- STAGE I
- STAGE II
- STAGE III
- STAGE IV
- RECURRENT
Therapy
- SURGERY
- RADIATION THERAPY
- CHEMOTHERAPY
- TARGETED THERAPY
- INHIBITORS
Drugs
- OPDIVO
- YERVOY
- MEKINIST+TAFINLAR
- KEYTRUDA
- COTELLIC
- ZELBORAF
- IMLYGIC
- GENERIC DRUGS
Global Malignant Melanoma Treatment Market Regional Analysis/Insights
The global malignant melanoma treatment market is analyzed and market size insights and trends are provided by country, stage, therapy and drugs as referenced above.
The countries covered in the global malignant melanoma treatment market report are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina, and rest of South America.
North America dominates the global malignant melanoma treatment market because of the increasing healthcare initiatives, the strong presence of major players in the market, increasing cases of melanoma and rising number of research activities in this region.
Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote awareness, growing research activities in the region, availability of massive untapped markets, large population pool, and the growing demand for quality healthcare in the region.
The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like downstream and upstream value chain analysis, technical trends, Porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The global malignant melanoma treatment market also provides you with detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the global malignant melanoma treatment market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the global malignant melanoma treatment market. The data is available for the historic period 2010-2020.
Competitive Landscape and Global Amphotericin B Market Share Analysis
The global malignant melanoma treatment market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the market.
Some of the major players operating in the global malignant melanoma treatment market are:
- Biogen (US)
- Bristol-Myers Squibb Company (US)
- Enzon Pharmaceuticals Inc. (US)
- GlaxoSmithKline plc (UK)
- Aptose Biosciences (Canada)
- Merck KGaA (Germany)
- ONO PHARMACEUTICAL CO. LTD.(Japan)
- DAIICHI SANKYO COMPANY LIMITED (Japan)
- Reliance Industries Limited (India)
SKU-